Results 221 to 230 of about 682,778 (301)

Arterial Hypertension [PDF]

Nature, 1963
openaire   +1 more source

Around and Through: Successful Mitral Paravalvular Leakage Closure Using Both Anterograde and Retrograde Approaches

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Paravalvular leak (PVL) is a recognized complication after surgical mitral valve replacement and may cause heart failure, pulmonary hypertension, or hemolysis when moderate or severe. Although redo surgery is the definitive treatment, it carries substantial risk in elderly patients or those with multiple prior cardiac surgeries.
Marco Garaventa, Luca Nai Fovino, Tommaso Fabris, Giuseppe Tarantini   +3 more
wiley   +1 more source

Prognostic Role of Platelets in Pulmonary Arterial Hypertension. [PDF]

Pulm Circ
Fernandes CJCDS, Nascimento IAO, Oliveira T, Jardim CVP, Hoette S, de Souza R.   +5 more
europepmc   +1 more source

Outcomes of Left Atrial Appendage Occlusion in Heart Failure With Reduced Ejection Fraction

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Patients with heart failure with reduced ejection fraction (HFrEF) were excluded from major trials of left atrial appendage occlusion (LAAO). Aim The objective of this study was to describe this population and evaluate outcomes after LAAO in patients with and without HFrEF.
Aamer Ubaid, Arindam Bagga, Kevin Kennedy, John T. Saxon, Chetan P. Huded   +4 more
wiley   +1 more source

The NOTCH3 extracellular domain is a serum biomarker for pulmonary arterial hypertension. [PDF]

Nat Med
Hernandez M, Winicki NM, Puerta CD, Lakshminarayanan S, Zhang Y, Ramirez-Sanchez I, Besse CE, Liu L, Poch DS, Yuan JX, Shyy JY, Yu PB, Garcia JGN, Thistlethwaite PA.   +13 more
europepmc   +1 more source

Variability in ACT Response to Standard UFH Bolus During PCI: A Prospective Study on Determinants of Subtherapeutic Anticoagulation

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Unfractionated heparin (UFH) remains the standard anticoagulant during percutaneous coronary intervention (PCI), with guidelines recommending a target activated clotting time (ACT) of ≥250 s. However, despite receiving a standardized bolus dose, many patients fail to achieve this target.
Manh Cuong Vu, Antonin Trimaille, Amandine Granier, Adrien Carmona, Anis Elidrissi, Marion Kibler, Laurence Jesel, Patrick Ohlmann, Laurent Sattler, Olivier Morel   +9 more
wiley   +1 more source

3D echo derived right ventricular principal surface strain in pulmonary arterial hypertension. [PDF]

Am J Physiol Heart Circ Physiol
Oakland HT, Bellumkonda L, Sugeng L, Joseph P, Kundu P, Izzi D, Zalik F, McCabe S, Raza A, Amendola R, Heerdt PM, Hunter KS, Singh I.   +12 more
europepmc   +1 more source

Successful Revascularization of Chronic Total Occlusions in Patients With Chronic Thromboembolic Pulmonary Disease

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Chronic thromboembolic pulmonary disease (CTEPD) leads to chronic total occlusions (CTOs) of the pulmonary arteries in a minority of patients. Treatment of CTOs with balloon pulmonary angioplasty (BPA) may substantially improve patient hemodynamics but presents unique technical challenges and has previously been associated with a ...
Elliot J. Stein, Peter J. Leary, Lauren N. Carlozzi, Samuel G. Rayner, Zachary L. Steinberg   +4 more
wiley   +1 more source

A study on the accessibility and utilisation of targeted drugs for pulmonary arterial hypertension in China. [PDF]

Front Pharmacol
Li W, Zhang H, Xu L, Tang W, Lu W, You Z, Wu H, Lin Y, Chen H.   +8 more
europepmc   +1 more source